BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 996 filers reported holding BAXTER INTL INC in Q2 2015. The put-call ratio across all filers is 0.74 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $1,136,000 | +17.8% | 18,768 | +0.9% | 0.08% | +19.7% |
Q1 2017 | $964,000 | +83.6% | 18,595 | +57.1% | 0.07% | +78.4% |
Q4 2016 | $525,000 | -4.2% | 11,839 | +2.9% | 0.04% | -7.5% |
Q3 2016 | $548,000 | +40.9% | 11,503 | +12.7% | 0.04% | +53.8% |
Q4 2015 | $389,000 | +17.2% | 10,207 | +0.9% | 0.03% | +13.0% |
Q3 2015 | $332,000 | -95.3% | 10,113 | -89.9% | 0.02% | -94.1% |
Q2 2015 | $7,020,000 | -28.0% | 100,385 | -29.5% | 0.39% | -34.2% |
Q1 2015 | $9,753,000 | +34.1% | 142,386 | +43.5% | 0.60% | +40.9% |
Q4 2014 | $7,273,000 | -30.5% | 99,242 | -32.0% | 0.42% | -23.4% |
Q3 2014 | $10,472,000 | +17.8% | 145,915 | +18.6% | 0.55% | +29.6% |
Q2 2014 | $8,892,000 | -6.7% | 122,983 | -5.1% | 0.43% | +6.2% |
Q1 2014 | $9,533,000 | -10.5% | 129,558 | -15.4% | 0.40% | -0.7% |
Q4 2013 | $10,652,000 | -1.9% | 153,159 | -7.3% | 0.40% | +9.8% |
Q3 2013 | $10,853,000 | – | 165,212 | – | 0.37% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
13D Management LLC | 194,807 | $11,794,000 | 4.18% |
Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |